Skip to main content
Clinical Trials/JPRN-UMIN000022129
JPRN-UMIN000022129
Completed
未知

The clinical trials for safety and usefulness of chronic hepatitis therapeutics,agent 3-oxygelmillpropionic acid polymer for the advanced and recurrent colorectal cancer of having the existing chemotherapeutic refractory or intolerance.(Phase 1 test) - Propagermanium test

Osaka University Hospital0 sites5 target enrollmentApril 28, 2016

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Osaka University Hospital
Enrollment
5
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 28, 2016
End Date
March 31, 2020
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • (1\)Patients with active double cancer.(2\)Patients with serious drug hypersensitivity or with a history of drug allergy.(3\)Patients with serious complications.(4\)Patients with jaundice,cirrhosis or with suspected cirrhosis of the liver.(5\)There is a history of chronic hepatitis B, and in the present study drug has already been ingested.(6\)Patients with active infection.(7\)Women who have a possibility of or in the pregnancy,who hope to become pregnant,or who are breast\-feeding. Men who wish to become pregnant partner.(8\)Patients with severe mental disorder.(9Other patients whom the physician decided to be unsuitable for safely carrying out the present study.

Outcomes

Primary Outcomes

Not specified

Similar Trials